Dafna Capital Management LLC Next Cure, Inc. Transaction History

Dafna Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.84 $27,749 - $39,580	-21,511 Reduced 11.46%	166,185 $214,000
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $23,968 - $38,265	4,205 Added 2.29%	187,696 $1.13 Million
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $900,531 - $1.22 Million	118,491 Added 182.29%	183,491 $1.47 Million
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $189,400 - $248,600	-20,000 Reduced 23.53%	65,000 $709,000
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $529,750 - $1.38 Million	65,000 Added 325.0%	85,000 $748,000
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $500,000 - $1.84 Million	20,000 New	20,000 $1.13 Million
Q3 2019 Nov 14, 2019	SELL	$15.73 - $41.6 $1.51 Million - $4 Million	-96,100 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.16 - $20.64 $1.36 Million - $1.98 Million	96,100 New	96,100 $1.44 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $21.1M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.